Connect with us

Government

Fauci “Needs To Put Up Or Shut Up”, ‘America’s Doctor’ Dismantled In Scathing Op-Ed

Fauci "Needs To Put Up Or Shut Up", ‘America’s Doctor’ Dismantled In Scathing Op-Ed

Doubts about the omnipotent oracular-ness of "America’s Doctor" are starting to spread… and not just among the extreme-right-nazi-anti-vaxx-COVID-deniers…

Published

on

Fauci "Needs To Put Up Or Shut Up", 'America's Doctor' Dismantled In Scathing Op-Ed

Doubts about the omnipotent oracular-ness of "America's Doctor" are starting to spread... and not just among the extreme-right-nazi-anti-vaxx-COVID-deniers (that constitute anyone who ever raises any doubts about any aspect of Biden/Fauci's public health policy).

The coronavirus pandemic has been a great tragedy, there can be no doubt about that. But, as Scott Atlas recently noted, it has also exposed profound issues in America that now threaten the very principles of freedom and order that we Americans often take for granted.

First, I have been shocked at the enormous power of the government, to unilaterally decree, to simply close businesses and schools by edict, restrict personal movement, mandate behavior, and eliminate our most basic freedoms, without any end and little accountability.

Second, I remain surprised at the acceptance by the American people of draconian rules, restrictions, and unprecedented mandates, even those that are arbitrary, destructive, and wholly unscientific.

This crisis has also exposed what we all have known existed, but we have tolerated for years: the overt bias of the media, the lack of diverse viewpoints on campuses, the absence of neutrality in big tech controlling social media, and now more visibly than ever, the intrusion of politics into science. Ultimately, the freedom to seek and state the truth is at risk here in the United States.

Questions about virus transmission, mask effectiveness, lockdown cost/benefits, school safety, child vaccinations, and most recently immigrant infections have all left the American people questioning their own sanity as Fauci flips and flops and shifts goalposts at will.

And, as Mike Shedlock reports, Dr. Anthony Fauci took questions from US Senators in Congress a few days ago. He was successful at not answering much of anything.

At a hearing this week, Sen. Roger Marshall questioned Dr. Anthony Fauci and CDC Director Rochelle Walensky on COVID-19 spreading due to the surge of migrants at the border.

Dr. Fauci is very skilled at ducking questions. 

My favorite clip is toward the end of the video. 

Marshall: Dr. Fauci, are you comfortable with what we are doing on the border from an ID standpoint?

Dr. Fauci: The reason I have to hedge on that is that I am not really very deeply familiar with the details of what's going on at the border.

Marshall: Whose job is it to know that?

Nothing seems to scare the establishment more than a return to 'normal'. And by 'normal', we mean a return to an environment outside of the tyrannical control of career politicians and bureaucrats who have got a taste for this 'being king' stuff and know that anyone who questions their edicts will be 'canceled' by their Covidian cultists.

But, in February, Johns Hopkins professor, Dr. Marty Makary, dared to pen an Op-ed in the WSJ saying that we will have herd immunity by April.

And as we previously noted, some awkward 'facts' and 'science' on that herd immunity were recently been dropped by none other than FundStrat's Tom Lee.

"...cumulatively and slowly, the US is seeing more states reach that combined level of vaccinations + infections approach what is seen as herd immunity.”

Source

So far, South Dakota, North Dakota, Rhode Island, Arizona, Oklahoma, Utah, and Tennessee are the nearest.

Lee's "math" - which we also know is racist - appears to fit with Makary's arguments for why the recent plunge in cases, hospitalizations, and deaths is not policy-related (no matter how much the politicians and their media lackeys push that narrative):

 "...the consistent and rapid decline in daily cases since Jan. 8 can be explained only by natural immunity. Behavior didn’t suddenly improve over the holidays; Americans traveled more over Christmas than they had since March. Vaccines also don’t explain the steep decline in January. Vaccination rates were low and they take weeks to kick in."

"Experts should level with the public about the good news..." exclaimed Makary, and this data on imminent herd immunity puts more pressure on Fauci and Biden to come clean... despite their variant-fearmongering and "no return to normal until Christmas or beyond" predictions.

But of course, this reality may never be allowed in the national narrative, as Makary previously concluded:

"Some medical experts privately agreed with my prediction that there may be very little Covid-19 by April but suggested that I not to talk publicly about herd immunity because people might become complacent and fail to take precautions or might decline the vaccine. But scientists shouldn’t try to manipulate the public by hiding the truth. As we encourage everyone to get a vaccine, we also need to reopen schools and society to limit the damage of closures and prolonged isolation. Contingency planning for an open economy by April can deliver hope to those in despair and to those who have made large personal sacrifices."

But, it appears he has ignored those suggestions as overnight, Marty Makary threw some more shade at Fauci over his herd immunity ignorance in another Wall Street Journal op-ed, saying that herd immunity in America is close, despite Fauci's denial.

He begins by taking direct aim at Fauci's "science"...

"Anthony Fauci has been saying that the country needs to vaccinate 70% to 85% of the population to reach herd immunity from Covid-19. But he inexplicably ignores natural immunity. If you account for previous infections, herd immunity is likely close at hand.

...

Undercounting or removing the many Americans with natural immunity from any tally of herd immunity is a scientific error of omission. When people wonder why President Biden talks about limiting Fourth of July gatherings, it’s because his most prominent medical adviser has dismissed the contribution of natural immunity, artificially extending the timeline."

Makary goes to note that after a year of millions of Covid-19 cases in the U.S., it’s clear that reinfections are rare.

"Natural immunity is real and shouldn’t be ignored."

Rochelle Walensky, director of the Centers for Disease Control and Prevention, has toed the line, joining Dr. Fauci in playing down natural immunity.

Dr. Fauci has said that we don’t have good data on natural immunity. That is largely because his own National Institutes of Health has done little to answer this and other important clinical questions.

The NIH and CDC, which together receive more than $40 billion a year from taxpayers, should have focused on answering the most basic Covid-19 clinical questions that affect Americans.

Makary concludes with some common sense, that seems wholly lacking from the conversation currently:

"If we say we’re going to follow the science, then we need to be willing to consider all the data."

But hey, just "obey' and Fauci and Biden will let you know what freedoms will be re-gifted back to you soon...

Finally, we give Senator Rand Paul the last word, who after grilling Fauci in recent hearings, took his fight the "America's doctor" to Fox News this week. As SaraACarter.com's Annaliese Levy reports, Paul spoke with host Neil Cavuto to talk about his recent exchanges with Dr. Fauci regarding forcing people to wear face masks after they have received the coronavirus vaccine.

“If the government is going to tell you can’t go anywhere unless you’re wearing a mask, they should tell you why and they should present the evidence,” Paul said.

Paul is asking the government to provide evidence that those who have been infected with the coronavirus or those that have been vaccinated are still transmitting the disease.

Paul went on to describe Fauci’s approach to masks as “emotionalism and fear-mongering.”

“Dr. Fauci needs to put up or shut up,” Paul told Cavuto.

“He needs to show us the scientific evidence that it’s a problem after you’ve been vaccinated or after you’ve already got the disease naturally.”

Paul explained that if Fauci presented evidence proving that vaccinations or prior infection were not effective against new virus variants, he would reassess his stance on masks.

“But so far all he’s telling me is his opinion,” Paul said.

“Really their opinion is, look, they had another one of these vaccine doctors on television, he was like, ‘Oh, it’s about civility.’ Civility is not science. For goodness sakes, show us some evidence to back up these mandates.

Cavuto asked Paul if he has continued to follow the mask mandate after receiving the vaccination.

“We do what we’re forced to do to live in Dr. Fauci’s world,” Paul said.

Tyler Durden Thu, 03/25/2021 - 17:20

Read More

Continue Reading

International

Analyst reviews Apple stock price target amid challenges

Here’s what could happen to Apple shares next.

Published

on

They said it was bound to happen.

It was Jan. 11, 2024 when software giant Microsoft  (MSFT)  briefly passed Apple  (AAPL)  as the most valuable company in the world.

Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion. 

It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion. 

"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.

The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.

Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue. 

Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.

Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.

“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.

A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.

Future Publishing/Getty Images

Big plans for China

Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.

Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.

Related: Tech News Now: OpenAI says Musk contract 'never existed', Xiaomi's EV, and more

The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.

Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.

Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.

"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads. 

"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.

Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify  (SPOT)  and other music streaming rivals via restrictions on the App Store.

The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.

Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com

The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.

BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market. 

Analyst says Apple selloff 'overdone'

Concurrently, prices for previous models are typically reduced by about $100 with each new release. 

This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.

More Tech Stocks:

Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.

This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China. 

BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.

The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.

On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”

The firm said that investors' growing preference for AI-focused stocks like Nvidia  (NVDA)  has led to a reallocation of funds away from Apple. 

In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.

And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.

“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…

Published

on

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

Credit: IVI

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

 

The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.

 

There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.

 

“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”

 

In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.

 

There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.

 

Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.

 

Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”

 

As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

CONTACT

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int


Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Trending